Last reviewed · How we verify
Maintenance weekly x4
This drug targets the CD19 protein on B cells to induce apoptosis.
This drug targets the CD19 protein on B cells to induce apoptosis. Used for Relapsed or refractory diffuse large B-cell lymphoma, Relapsed or refractory follicular lymphoma, Relapsed or refractory mantle cell lymphoma.
At a glance
| Generic name | Maintenance weekly x4 |
|---|---|
| Also known as | Rituximab |
| Sponsor | Fondazione Italiana Linfomi - ETS |
| Drug class | Monoclonal antibody |
| Target | CD19 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CD19 is a protein found on the surface of B cells, and targeting it with this drug leads to the destruction of these cancerous cells. This approach is particularly effective in treating certain types of lymphoma.
Approved indications
- Relapsed or refractory diffuse large B-cell lymphoma
- Relapsed or refractory follicular lymphoma
- Relapsed or refractory mantle cell lymphoma
- Relapsed or refractory marginal zone lymphoma
- Relapsed or refractory small lymphocytic lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Infections
- Fatigue
Key clinical trials
- Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma (PHASE3)
- Effects of Physical Exercise on Response to Treatement in Breast Cancer (NA)
- Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma (PHASE2)
- Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma (PHASE2)
- Intensive Group Based CIMT for Young Children (NA)
- Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT (PHASE1, PHASE2)
- IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer (PHASE2)
- Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Maintenance weekly x4 CI brief — competitive landscape report
- Maintenance weekly x4 updates RSS · CI watch RSS
- Fondazione Italiana Linfomi - ETS portfolio CI